Metabolic & Weight Management

Petrelintide

Also known as ZP8396 · long-acting amylin analog

Emerging researchSubcutaneous injectionInvestigational only. Petrelintide is not approved by the FDA or any other regulatory authority and remains in clinical development (Phase 3 planned as of 2026). As an unapproved investigational drug, it is not a lawful dietary supplement ingredient and is not an FDA-recognized bulk drug substance for 503A/503B pharmacy compounding. Amylin/calcitonin-receptor agonists are not currently named as a prohibited class on the WADA Prohibited List, but athletes should verify any compound against the current WADA rules before use.

Petrelintide (ZP8396) is an investigational long-acting analog of the human hormone amylin, developed by Zealand Pharma and partnered with Roche for once-weekly subcutaneous administration. It acts as a balanced agonist at amylin and calcitonin receptors, mechanisms associated with promoting satiety and slowing gastric emptying; in preclinical research, amylin signaling has also been linked to improved sensitivity to leptin, an adipose-derived appetite-regulating hormone. It has been engineered for stability at neutral pH to reduce fibrillation, a formulation challenge seen with earlier amylin analogs. Positive Phase 2 results (ZUPREME-1) reported in 2026 described clinically meaningful weight reduction with a tolerability profile reported as comparable to placebo, and a Phase 3 program is planned. As an investigational compound, it has not been approved by any regulatory authority and its long-term safety and efficacy remain under study.

Studied / used for

Investigated for chronic weight management in people with overweight or obesity
Studied for weight reduction in people with overweight or obesity and type 2 diabetes
Investigated for gastrointestinal tolerability relative to GLP-1 receptor agonists
Studied as a potential combination partner with incretin-based peptides such as semaglutide

Commonly reported side effects

Nausea (the most commonly reported adverse event in trials)
Injection-site reactions, commonly reported as mild and transient
Diarrhea, commonly reported
Constipation, commonly reported
Vomiting, reported in trials

Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds